FindTrial
Sign In

Clinical diagnosis of breast BI-RADS 4 with cellular free RNA and MRI Imageomics

Effect of plasma cellular free RNA combined with MRI Imageomics on clinical decision-making in breast BI-RADS4 lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076187
Enrollment
Unknown
Registered
2023-09-27
Start date
2023-09-30
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast neoplasms

Interventions

Gold Standard:Results of pathology and immunohistochemistry
Index test:MRI cfRNA

Sponsors

General Hospital of Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) the image quality was good, (2) the breast cancer was detected by immunohistochemistry with pathological results, (3) the patients did not receive any intervention therapy before MRI and plasma CFRNA detection; (4) the patients were not complicated with other malignant tumors.

Exclusion criteria

Exclusion criteria: The exclusion criteria were: (1) the interval between examination and operation or puncture was more than 1 month, (2) the clinical and pathological data were not complete, (3) the patients refused the detection of plasma CfRNA.

Design outcomes

Primary

MeasureTime frame
MRI Imageomics;Cell free RNA;accuracy;specificity;—

Countries

China

Contacts

Public ContactWang Pei

General Hospital of Ningxia Medical University

742594151@qq.com+86 137 0958 9576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026